×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMRN – amarin corporation plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
7/15
08:00 am
amrn
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Low
Report
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
7/1
04:19 am
amrn
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape [Yahoo! Finance]
Medium
Report
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape [Yahoo! Finance]
6/30
04:15 pm
amrn
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Medium
Report
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
6/18
06:33 am
amrn
Amarin (AMRN) was upgraded by Zacks Research from "hold" to "strong-buy".
Low
Report
Amarin (AMRN) was upgraded by Zacks Research from "hold" to "strong-buy".
5/27
08:00 am
amrn
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Low
Report
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
5/20
07:33 am
amrn
Amarin (AMRN) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Amarin (AMRN) was downgraded by Zacks Research from "strong-buy" to "hold".
4/30
11:05 am
amrn
Amarin (AMRN) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
Low
Report
Amarin (AMRN) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
4/30
07:51 am
amrn
Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ... [Yahoo! Finance]
Medium
Report
Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ... [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
4/29/2026
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
4.3%
amarin corporation plc - american depositary shares
10/29/2025
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
-14.8%
amarin corporation plc - american depositary shares
7/30/2025
07:00 am
amrn
amarin corporation plc - american depositary shares
BEAT
Report
3.2%
amarin corporation plc - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
7/15
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Fishman Peter L.
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Fishman Peter L.
7/15
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Provoost Jonathan
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Provoost Jonathan
7/15
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Keenan David Paul
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Keenan David Paul
7/15
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Ketchum Steven B
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Ketchum Steven B
6/30
05:20 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jun 26 Filed by: Berg Aaron
Medium
Report
Form 4 AMARIN CORP PLC\UK For: Jun 26 Filed by: Berg Aaron
4/22
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Bonfiglio Patrice Eadon
Low
Report
Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Bonfiglio Patrice Eadon
4/21
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: O'Connor Oliver
Low
Report
Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: O'Connor Oliver
4/21
05:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Horn Keith
Low
Report
Form 4 AMARIN CORP PLC\UK For: Apr 18 Filed by: Horn Keith
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at Citigroup Inc from $24.00 to $6.00. They now have a "buy" rating on the stock.
25.4%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
TOP News Decliners
3/15
Amarin Takes Proactive Steps to Support Public Health Priorities
-17.6%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: